<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<article xlink="http://www.w3.org/1999/xlink" dtd-version="1.0" article-type="endocrinology" lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher">JOHS</journal-id>
      <journal-id journal-id-type="nlm-ta">Journ of Health Scien</journal-id>
      <journal-title-group>
        <journal-title>Journal of HealthCare Sciences</journal-title>
        <abbrev-journal-title abbrev-type="pubmed">Journ of Health Scien</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">2231-2196</issn>
      <issn pub-type="opub">0975-5241</issn>
      <publisher>
        <publisher-name>Radiance Research Academy</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">403</article-id>
      <article-id pub-id-type="doi">http://dx.doi.org/10.52533/JOHS.2025.50603</article-id>
      <article-id pub-id-type="doi-url"/>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Endocrinology</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Evaluating the Impact of Growth Hormone Deficiency Treatments on Quality of Life&#13;
</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>AlMutairi</surname>
            <given-names>Abdullah Moneef</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Alshahrani</surname>
            <given-names>Mushabab Ali</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Basaba</surname>
            <given-names>Abdullah Sameer</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Royba</surname>
            <given-names>Sabah Abdulrahman Al</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Alghamdi</surname>
            <given-names>Abdulaziz Saad</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mohammed</surname>
            <given-names>Saeed Abdulsattar</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>AlQahtani</surname>
            <given-names>Khadejah Mofreh</given-names>
          </name>
        </contrib>
      </contrib-group>
      <pub-date pub-type="ppub">
        <day>13</day>
        <month>06</month>
        <year>2025</year>
      </pub-date>
      <volume>5</volume>
      <issue>6</issue>
      <fpage>196</fpage>
      <lpage>203</lpage>
      <permissions>
        <copyright-statement>This article is copyright of Popeye Publishing, 2009</copyright-statement>
        <copyright-year>2009</copyright-year>
        <license license-type="open-access" href="http://creativecommons.org/licenses/by/4.0/">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Childhood and adult patients with growth hormone deficiency (GHD) experience a variety of physical, metabolic, and psychological problems that collectively lower quality of life (QoL). Recombinant human growth hormone (rhGH) has transformed treatment by improving growth body composition, energy levels, and mental health. Nevertheless, further research is needed to determine the full scope of these QoL gains. This review of the literature summarizes current research on how growth hormone (GH) replacement therapy affects GHD patients__ampersandsign#39; quality of life based on longitudinal studies, meta-analyses, and clinical trials. Although GH therapy has demonstrated advantages in several QoL areas, issues still exist, such as patient response variability, the sustainability of long-term treatment, and possible adverse effects. The effectiveness of GH therapy, the methods used to evaluate QoL outcomes, and the necessity of individualized treatment approaches are all clarified by this review__ampersandsign#39;s analysis of the most recent data. Future research should validate current QoL tools, assess the long-term safety of GH therapy, and develop improved methods for monitoring treatment outcomes to enhance personalized care and overall well-being in GHD patients.&#13;
</p>
      </abstract>
      <kwd-group>
        <kwd>Growth hormone deficiency (GHD)</kwd>
        <kwd> quality of life (QoL)</kwd>
        <kwd> growth hormone GH replacement</kwd>
        <kwd> Recombinant human growth hormone (rhGH)</kwd>
      </kwd-group>
    </article-meta>
  </front>
</article>